Liquid Biopsy for MASH
Metabolic dysfunction-associated steatohepatitis (MASH) detection and staging
Key Facts
About Hepta
Hepta is an AI-native diagnostics company founded in 2021, based in Cambridge, USA, with a focus on decoding liver biology from blood. Its core technology is a liquid biopsy platform that analyzes epigenetic signatures in cell-free DNA, paired with advanced machine learning, to non-invasively detect and monitor metabolic liver disease, specifically MASH. The company aims to address critical gaps in the current diagnostic pathway, which relies on invasive biopsies or scarce imaging, by providing a scalable blood test designed for early intervention. Led by a team with expertise in liquid biopsy, AI, and hepatology, Hepta is building a platform intended to expand into other serious chronic diseases.
View full company profile